BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises three approved products and multiple clinical and pre-clinical product candidates. Approved products include Naglazyme® (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme® (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; and Kuvan® (sapropterin dihydrochloride) Tablets, for phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany.

REGENX Biosciences is a biopharmaceutical company that develops therapeutics and research tools based on adeno-associated viral (AAV) vectors. The company offers NAV, a gene delivery technology that includes recombinant adeno-associated viral vectors. Its technology is used for the treatment of metabolic disorders, muscle diseases, hematologic disorders, ocular diseases, and neurodegenerative disorders; and clinical trails in therapeutic areas, such as inherited diseases, CNS disorders, heart failure, and vaccines. The company also offers reagent services for various applications, including molecular therapies, understanding biological activity, and target validation, creating disease models and screening in vivo, and genome-wide association studies. In addition, it offers custom products and services, including AAV plasmids, AAV Vector reporter systems, and custom AAV vectors to the researchers. The company is based in Washington, District Of Columbia.

biOasis Technologies, Inc. operates as a biopharmaceutical company. It focuses on research and development for the diagnosis and treatment of neurological disease and disorders such as brain cancers, neurodegenerative diseases, and metabolic disorders. Its products include the Transcend program as its proprietary carrier, p97 and imaging agents across the blood brain barrier. The company was founded by Robin B. Hutchison on November 3, 2006 and is headquartered in New Haven, CT.

ArmaGen, Inc. engages in operation of a clinical stage biotechnology company focused on developing revolutionary therapies for severe neurological disorders. Its products include AGT-110-Brain-penetrating biologic tumor necrosis factor inhibitor (TNFI) for Alzheimer's disease, AGT-115-Brain-penetrating erythropoietin (EPO) for stroke, AGT-160-Brain penetrating anti-amyloid antibody (AAA) for Alzheimer's disease and AGT-181-Brain-penetrating iduronidase (IDUA) for Mucopolysaccharidosis (MPS) Type I (Hurler's syndrome). The company was founded by William M. Pardridge and Ruben J. Boado in 2003 and is headquartered in San Diego, CA.

JCR Pharmaceuticals Co., Ltd. engages in the manufacture and sale of pharmaceutical products. It operates through the following segments: Pharmaceutical Business; and Medical and Research Equipment Business. The Pharmaceutical Business segment deals with the manufacture, purchase, and sale of ethical drugs, active pharmaceutical ingredients, and raw materials. The Medical and Research Equipment Business segment sells medical devices and laboratory equipment. The company was founded by Shin Ashida on September 13, 1975 and is headquartered in Ashiya, Japan.

AngioChem is a clinical-stage biotechnology discovering and developing new breakthrough drugs that are uniquely capable of crossing the blood-brain barrier to treat brain diseases. Their EPiC platform solves the key problem for crossing the blood-brain barrier by developing novel drugs that use a receptor-based approach. These novel Engineered Peptide Compounds (EPiC) have the potential to address significant medical needs, many of which cannot be effectively addressed due to the fundamental physiological challenge the blood-brain barrier presents for therapeutic intervention.

Sanofi Genzyme is the specialty care global business unit of Sanofi, focused on rare diseases, multiple sclerosis, immunology, and oncology. They help people with debilitating and complex conditions that are often difficult to diagnose and treat. They are dedicated to discovering and advancing new therapies, providing hope to patients and their families around the world. Genzyme became part of Sanofi in 2011. While continuing to focus on rare diseases, they also established ourselves as a leader in the field of multiple sclerosis. In 2016, their focus expanded to include Sanofi’s programs in oncology and immunology. Their approach is shaped by a long history of developing highly specialized treatments and forging close relationships with physician and patient communities. Founded as Genzyme in Boston in 1981, they rapidly grew to become one of the world’s leading biotechnology companies, recognized for their pioneering development of treatments for rare genetic disorders and their innovative contributions to medical science and biomanufacturing.

Alexion Pharmaceuticals is a biopharmaceutical company, which is engaged in the discovery, development, and commercialization of biologic therapeutic products aimed at treating patients with severe and life-threatening disease states, including hematologic, kidney and neurologic diseases, transplant rejection, cancer, and autoimmune disorders. Its marketed product Soliris (eculizumab) is a therapy approved for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH). In April 2009 and August 2009, the United States food and drug administration (FDA) and the European Commission (E.C.), respectively, granted Soliris orphan drug designation for the treatment of patients with atypical Hemolytic Uremic Syndrome (aHUS). In December 2009, its Rhode Island manufacturing facility received regulatory approval from the E.C. Or the production of Soliris.

PerkinElmer Health Sciences, Inc. engages in the manufacture and distribution of analytical instruments. The company is headquartered in Waltham, MA.

Synageva BioPharma Corp. is a biopharmaceutical company which focuses on the discovery, development, and commercialization of therapeutic products for patients with life-threatening rare diseases and high unmet medical need. The company is currently evaluating sebelipase alfa in global clinical trials for LAL Deficiency, a lysosomal storage disease associated with liver damage and accelerated atherosclerosis in children and adults, and in infants, premature death often before six months of age. Synageva BioPharma was founded in 1993 and is headquartered in Lexington, MA.

CURNA, Inc. was engaged in manufacturing pharmaceutical products. The company was headquartered in Jupiter, FL.

Sangamo BioSciences is a clinical stage biopharmaceutical company involved in gene therapy that is researching ways of commercializing Zinc finger nucleases which modify a cell's DNA at an exact location thereby correcting or disrupting a specific gene. Sangamo BioSciences' lead therapy, SB-728, is a potential functional cure for HIV/AIDS. SB-728 works by removing some of the immune cells from the patient's blood that HIV attacks. The blood is sent to a lab which applies the SB-728 treatment to the patient's immune cells. The treatment removes the protein gateway on the immune cells that HIV needs to infect. The treated cells are then infused back into the patient whereby they reproduce and take over as HIV attacks and kills the non-treated cells. The treated, resistant cells thereby control the HIV infection and thus cures the patient from opportunistic infections that result from HIV. Recent published data further support the company's ongoing progress which has been described as "a major step toward immunological functional control of HIV."

Immusoft is a biotechnology company that is commercializing technology to program the human immune system by modifying the DNA in immune cells. The core components of Immusoft’s Immune System Programming (ISP) technology was developed in the Baltimore Lab at the California Institute of Technology (Caltech) and exclusively licensed by Immusoft. The technology instructs a patient’s cells to produce gene-encoded medicines (biologics). Cells that are reprogrammed using ISP become miniature drug factories that are expected to survive in patients for many years. It was founded in 2009 and is headquartered in Seattle, Washington.

Beijing Jude Pharmaceutical Technology Co., Ltd., established on 2019-07-16, Business scope includes general items:Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;Manufacturing of Specialty Chemical Products(Free of Hazardous Chemicals);Specialty Chemicals Sales(Free of Hazardous Chemicals);software development;Machinery sales.(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)licensed items:Drug retail.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,The specific business items are subject to the approval documents or licenses of relevant departments)(Do not engage in the business activities of projects prohibited and restricted by the industrial policies of the state and this city.)

Beijing Zhongke Medical Laboratory Co., Ltd., established on 2012-04-26, The scope of business includes medical laboratory:clinical chemistry laboratory;Clinical Cytomolecular Genetics Major;Technical Services.(Market entities independently choose business projects in accordance with the law,Carry out business activities;Items subject to approval by law,Carry out business activities in accordance with the approved content after approval by relevant departments;Do not engage in the business activities of projects prohibited and restricted by the industrial policies of the state and this city.)

Heyuan Biotechnology is a national high-tech enterprise specializing in the R&D of plant-derived recombinant protein expression technology. It has established a complete industrialization system and quality assurance system for plant-derived biopharmaceuticals in my country. The plant-derived recombinant protein production line has become an internationally renowned biomedical R&D center focusing on plant-based drug R&D and product development.

The Institute Pasteur is a private, non-profit foundation. Its mission is to help prevent and treat diseases, mainly those of infectious origin, through research, teaching, and public health initiatives.The Institut Pasteur is a research center of international renown ideally located in the very heart of Paris. Each year the institute hosts a multitude of scientific and medical conferences and meetings as well as events on a variety of themes.

Established in 1973 in Korea, Hanmi Pharmaceuticals now is one of the top 5 pharmaceutical companies in terms of revenue, and the most R&D focused company with the highest R&D investment for several years. Hanmi has been successful for a few decades with high flexibility, continuously changing its market/development strategy from first generics to IMD & FDC (Incrementally Modified Drug and Fixed Dose Combination) to new drug development including innovative small molecules and biologics. During the period of significant changes, Hanmi made multiple strategic collaboration relationships with multinational companies and biotech companies. Based on the success in 1980s and 1990s, Hanmi started its Chinese operation in 1996 with establishment of Beijing Hanmi. Now, Beijing Hanmi grew as a well-localized and well-settled Chinese company with more than 1,300 staffs including R&D, sales / marketing, and manufacturing experts and significant growth rate higher than 20% every year. Currently, Hanmi and Beijing Hanmi is closely collaborating on various business opportunities and new drug development projects as well as sales and marketing in Chinese territories. As the only Asian company with significant presence both in Korea and China, as the most R&D focused company with number of clinical stage projects with competitiveness, and as the company with open innovation based on multiple development/marketing collaborations, Hanmi is trying to develop and provide differentiated treatment options to patients suffering from various disease.